Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides - PubMed (original) (raw)

. 2011 Dec 8;54(23):8148-60.

doi: 10.1021/jm201071e. Epub 2011 Nov 4.

Affiliations

• PMID: 22007676
• PMCID: PMC3228886
• DOI: 10.1021/jm201071e

Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides

Geetanjali Agnihotri et al. J Med Chem. 2011.

Abstract

Toll-like receptor 2-agonistic lipopeptides typified by S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine (PAM(2)CS) compounds are potential vaccine adjuvants. In continuation of previously reported structure-activity relationships on this chemotype, we have determined that at least one acyl group of optimal length (C(16)) and an appropriately oriented ester carbonyl group is essential for TLR2-agonistic activity. The spacing between one of the palmitoyl ester carbonyl and the thioether is crucial to allow for an important H-bond, which observed in the crystal structure of the lipopeptide:TLR2 complex; consequently, activity is lost in homologated compounds. Penicillamine-derived analogues are also inactive, likely due to unfavorable steric interactions with the carbonyl of Ser 12 in TLR2. The thioether in this chemotype can be replaced with a selenoether. Importantly, the thioglycerol motif can be dispensed with altogether and can be replaced with a thioethanol bridge. These results have led to a structurally simpler, synthetically more accessible, and water-soluble analogue possessing strong TLR2-agonistic activities in human blood.

PubMed Disclaimer

Figures

Similar articles

• Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.
  Salunke DB, Shukla NM, Yoo E, Crall BM, Balakrishna R, Malladi SS, David SA. Salunke DB, et al. J Med Chem. 2012 Apr 12;55(7):3353-63. doi: 10.1021/jm3000533. Epub 2012 Mar 15. J Med Chem. 2012. PMID: 22385476 Free PMC article.
• Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.
  Salunke DB, Connelly SW, Shukla NM, Hermanson AR, Fox LM, David SA. Salunke DB, et al. J Med Chem. 2013 Jul 25;56(14):5885-900. doi: 10.1021/jm400620g. Epub 2013 Jul 10. J Med Chem. 2013. PMID: 23795818 Free PMC article.
• Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines.
  Lu BL, Williams GM, Verdon DJ, Dunbar PR, Brimble MA. Lu BL, et al. J Med Chem. 2020 Mar 12;63(5):2282-2291. doi: 10.1021/acs.jmedchem.9b01044. Epub 2019 Aug 30. J Med Chem. 2020. PMID: 31418565
• TLR2 agonists and their structure-activity relationships.
  Lu BL, Williams GM, Brimble MA. Lu BL, et al. Org Biomol Chem. 2020 Jul 15;18(27):5073-5094. doi: 10.1039/d0ob00942c. Org Biomol Chem. 2020. PMID: 32582902 Review.
• TLR2 Agonistic Small Molecules: Detailed Structure-Activity Relationship, Applications, and Future Prospects.
  Kaur A, Kaushik D, Piplani S, Mehta SK, Petrovsky N, Salunke DB. Kaur A, et al. J Med Chem. 2021 Jan 14;64(1):233-278. doi: 10.1021/acs.jmedchem.0c01627. Epub 2020 Dec 21. J Med Chem. 2021. PMID: 33346636 Review.

Cited by

• Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.
  Salunke DB, Yoo E, Shukla NM, Balakrishna R, Malladi SS, Serafin KJ, Day VW, Wang X, David SA. Salunke DB, et al. J Med Chem. 2012 Sep 27;55(18):8137-51. doi: 10.1021/jm301066h. Epub 2012 Sep 7. J Med Chem. 2012. PMID: 22924757 Free PMC article.
• Targeting Toll-like receptors with small molecule agents.
  Wang X, Smith C, Yin H. Wang X, et al. Chem Soc Rev. 2013 Jun 21;42(12):4859-66. doi: 10.1039/c3cs60039d. Chem Soc Rev. 2013. PMID: 23503527 Free PMC article. Review.
• Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.
  Kowalczyk R, Harris PWR, Williams GM, Yang SH, Brimble MA. Kowalczyk R, et al. Adv Exp Med Biol. 2017;1030:185-227. doi: 10.1007/978-3-319-66095-0_9. Adv Exp Med Biol. 2017. PMID: 29081055 Free PMC article. Review.
• Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.
  Kokatla HP, Sil D, Malladi SS, Balakrishna R, Hermanson AR, Fox LM, Wang X, Dixit A, David SA. Kokatla HP, et al. J Med Chem. 2013 Sep 12;56(17):6871-85. doi: 10.1021/jm400694d. Epub 2013 Aug 15. J Med Chem. 2013. PMID: 23899291 Free PMC article.
• Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.
  Huynh AS, Chung WJ, Cho HI, Moberg VE, Celis E, Morse DL, Vagner J. Huynh AS, et al. J Med Chem. 2012 Nov 26;55(22):9751-62. doi: 10.1021/jm301002f. Epub 2012 Nov 8. J Med Chem. 2012. PMID: 23098072 Free PMC article.

References

1. 1. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989;7:145–173. - PubMed
2. 1. Harris N, Gause WC. To B or not to B: B cells and the Th2-type immune response to helminths. Trends Immunol. 2011;32:80–88. - PMC - PubMed
3. 1. Romagnani S. Th1 and Th2 in human diseases. Clin. Immunol. Immunopathol. 1996;80:225–235. - PubMed
4. 1. O'Garra A, Murphy KM. From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat. Immunol. 2009;10:929–932. - PubMed
5. 1. Onoe K, Yanagawa Y, Minami K, Iijima N, Iwabuchi K. Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol. Res. 2007;38:319–332. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Chemical Information

  • BindingDB

• Miscellaneous

  • NCI CPTAC Assay Portal